- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novartis to Test Risk-Sharing Pricing Model for Heart Failure Drug Entresto
The Swiss drug giant Novartis is looking at alternate pricing models for its heart failure drug Entresto, which is expected to gain FDA approval in August.
The Swiss drug giant Novartis is looking at alternate pricing models for its heart failure drug Entresto, which is expected to gain FDA approval in August.
Proven to improve heart function in individuals with a reduced ejection fraction, Entresto, also called LCZ696, will probably earn significant annual revenue for Novartis, projected in the billions. However, according to David Epstein, division head of Novartis, the company is working with healthcare systems to introduce a new outcomes-based payment model, where the initial discounted rate will be balanced by increased payments to Novartis if the drug reduces hospital visits.
The healthcare industry is gradually moving towards such clinical-outcomes—based risk-sharing models, and Novartis has already has a system in place for this for it's multiple sclerosis drug Gilenya.
Read more at Reuters:
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
